scholarly journals Simultaneous Presentation of Hairy Cell Leukemia and Acute Lymphoblastic Leukemia

2021 ◽  
Vol 38 (4) ◽  
Author(s):  
Mingyong Li ◽  
Yuan He ◽  
Kang Jiang ◽  
Juan Zhang
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Hairy Cell Leukemia ◽  
Lymphoblastic Leukemia ◽  
Simultaneous Presentation ◽  
Hairy Cell ◽  
Cell Leukemia

scholarly journals Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes

Blood ◽  
1989 ◽  
Vol 73 (8) ◽  
pp. 2128-2132 ◽  
Author(s):  
DM Komp ◽  
J McNamara ◽  
P Buckley
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Hairy Cell Leukemia ◽  
Poor Prognosis ◽  
Lymphoblastic Leukemia ◽  
Interleukin 2 ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Adult T Cell Leukemia ◽  
Interleukin 2 Receptor ◽  
Soluble Interleukin 2 Receptor

The serum of children with untreated hemophagocytic syndromes contains elevated levels (23,600 to 75,200 U/mL) of soluble interleukin-2 receptor (SIL2R) that returns toward normal with clinical improvement. These levels are in excess of levels previously reported for benign conditions. They are as high as levels reported for HTLV-1-associated adult T-cell leukemia (HATL) and hairy cell leukemia (HCL) in adults and some children with poor-prognosis non-T, non-B, acute lymphoblastic leukemia (ALL). Serum SIL-2R is a marker of disease activity that has the potential to identify infants at risk for the inherited form of the disease before the disease is clinically expressed.

scholarly journals Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes

Blood ◽  
1989 ◽  
Vol 73 (8) ◽  
pp. 2128-2132 ◽  
Author(s):  
DM Komp ◽  
J McNamara ◽  
P Buckley
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Hairy Cell Leukemia ◽  
Poor Prognosis ◽  
Lymphoblastic Leukemia ◽  
Interleukin 2 ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Adult T Cell Leukemia ◽  
Interleukin 2 Receptor ◽  
Soluble Interleukin 2 Receptor

Abstract The serum of children with untreated hemophagocytic syndromes contains elevated levels (23,600 to 75,200 U/mL) of soluble interleukin-2 receptor (SIL2R) that returns toward normal with clinical improvement. These levels are in excess of levels previously reported for benign conditions. They are as high as levels reported for HTLV-1-associated adult T-cell leukemia (HATL) and hairy cell leukemia (HCL) in adults and some children with poor-prognosis non-T, non-B, acute lymphoblastic leukemia (ALL). Serum SIL-2R is a marker of disease activity that has the potential to identify infants at risk for the inherited form of the disease before the disease is clinically expressed.

Hairy Cell Leukemia-Specific Recognition by Multiple Autologous HLA-DQ or DP-Restricted T-Cell Clones

Blood ◽  
1999 ◽  
Vol 93 (1) ◽  
pp. 251-259
Author(s):  
Lisette van de Corput ◽  
Hanneke C. Kluin-Nelemans ◽  
Michel G.D. Kester ◽  
Roel Willemze ◽  
J.H. Frederik Falkenburg
Keyword(s):  
T Cells ◽  
T Cell ◽  
Hairy Cell Leukemia ◽  
Lymphoblastic Leukemia ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
T Cell Clones ◽  
Cell Clones ◽  
Hla Dq ◽  
T Cell Clone

We studied in patients with hairy cell leukemia (HCL) whether autoreactive T cells could be isolated with specific reactivity to the HCL cells. HCL cells were activated via triggering of CD40 on the cell membrane and used as stimulator cells to generate autologous T-cell clones. Two types of CD4+BV2+ T-cell clones with different CDR3 rearrangements and one type of CD4+BV8S3+ T-cell clone were generated from the spleen or blood. These clones specifically recognized the autologous HCL cells, without reactivity to autologous peripheral blood mononuclear cells (PBMC), phytohemagglutinin blasts, or Epstein-Barr virus–transformed B cells in a primed lymphocyte test. Blocking and panel studies using HCL cells from 11 other patients showed that recognition of the HCL cells by the BV2+ T cells was restricted by HLA-DQA1*03/DQB1*0301, and the BV8S3+ T cells were restricted by DPB1*04. The T-cell clones did not recognize DPB1*04+ or DQ3+ PBMC from healthy donors or DP/DQ matched malignant cells from patients with other hematologic malignancies, except for one patient with acute lymphoblastic leukemia. These HCL-specific T-cell clones may be used for the detection of an HCL-specific tumor antigen.

scholarly journals Simultaneous presentation of plasma cell myeloma and hairy cell leukemia

2019 ◽  
Vol 54 (2) ◽  
pp. 85-85
Author(s):  
Giovanni Carulli ◽  
Paola Sammuri ◽  
Virginia Ottaviano
Keyword(s):  
Plasma Cell ◽  
Hairy Cell Leukemia ◽  
Simultaneous Presentation ◽  
Plasma Cell Myeloma ◽  
Hairy Cell ◽  
Cell Leukemia

Hairy Cell Leukemia-Specific Recognition by Multiple Autologous HLA-DQ or DP-Restricted T-Cell Clones

Blood ◽  
1999 ◽  
Vol 93 (1) ◽  
pp. 251-259 ◽  
Author(s):  
Lisette van de Corput ◽  
Hanneke C. Kluin-Nelemans ◽  
Michel G.D. Kester ◽  
Roel Willemze ◽  
J.H. Frederik Falkenburg
Keyword(s):  
T Cells ◽  
T Cell ◽  
Hairy Cell Leukemia ◽  
Lymphoblastic Leukemia ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
T Cell Clones ◽  
Cell Clones ◽  
Hla Dq ◽  
T Cell Clone

Abstract We studied in patients with hairy cell leukemia (HCL) whether autoreactive T cells could be isolated with specific reactivity to the HCL cells. HCL cells were activated via triggering of CD40 on the cell membrane and used as stimulator cells to generate autologous T-cell clones. Two types of CD4+BV2+ T-cell clones with different CDR3 rearrangements and one type of CD4+BV8S3+ T-cell clone were generated from the spleen or blood. These clones specifically recognized the autologous HCL cells, without reactivity to autologous peripheral blood mononuclear cells (PBMC), phytohemagglutinin blasts, or Epstein-Barr virus–transformed B cells in a primed lymphocyte test. Blocking and panel studies using HCL cells from 11 other patients showed that recognition of the HCL cells by the BV2+ T cells was restricted by HLA-DQA1*03/DQB1*0301, and the BV8S3+ T cells were restricted by DPB1*04. The T-cell clones did not recognize DPB1*04+ or DQ3+ PBMC from healthy donors or DP/DQ matched malignant cells from patients with other hematologic malignancies, except for one patient with acute lymphoblastic leukemia. These HCL-specific T-cell clones may be used for the detection of an HCL-specific tumor antigen.

scholarly journals The phenotype of the neoplastic cells of hairy cell leukemia studied with monoclonal antibodies

Blood ◽  
1982 ◽  
Vol 59 (3) ◽  
pp. 609-614 ◽  
Author(s):  
J Jansen ◽  
TW LeBien ◽  
JH Kersey
Keyword(s):  
Monoclonal Antibodies ◽  
Hairy Cell Leukemia ◽  
Lymphoblastic Leukemia ◽  
Cell Lineage ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Hla Dr ◽  
Hairy Cells ◽  
B Lineage

Abstract Eighteen cases of hairy cell leukemia were studied with a battery of polyclonal anti-Ig and nine monoclonal antibodies to determine the lineage of the hairy cells (HC) and the stage of their maturation arrest. Hairy cells tend to nonspecifically bind many antisera and precautions had to be taken to avoid nonspecific fluorescence of the cells. All but one case was reactive with one light chain type and one or more heavy chain isotype antisera as reported before. All cases studied were positive for monomorphic HLA-DR determinants, using monoclonal antibody 7.2. Most cases tested (6/7) were positive with the B-lineage related antibody PI 153/3. While most cases (15/18) were nonreactive with the B-lineage related antibody BA-1, they became positive (5/5) following in vitro culture. Seven out of nine cases were reactive with OKM1. Common acute lymphoblastic leukemia antigen (CALLA) was absent in all (15) cases tested and the ALL associated structure p24/BA-2 was absent from 16 of 18 cases. HC from none of the cases were clearly positive with the T-cell antibodies 9.6., or TA-1, whereas in only 1/18 the cells reacted with T101. The results of this study support the B cell lineage of most HC, and show the presence of multiple phenotypes. In combination with the surface Ib present on the cells, a hierarchy of phenotypes is postulated, with SIg-ormu delta, BA- 1+, PI 153/3+, HLA-DR+ being the most immature, and SIg(alpha) gamma, BA-1-, PI 153/3-, HLA-DR+ the most mature.

scholarly journals Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval

2019 ◽  
Vol 3 (19) ◽  
pp. 2905-2910 ◽  
Author(s):  
Adam Yuh Lin ◽  
Shira Naomi Dinner
Keyword(s):  
Hairy Cell Leukemia ◽  
Residual Disease ◽  
Remission Rate ◽  
Lymphoblastic Leukemia ◽  
Disease Free Survival ◽  
Cell Surface Expression ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Recombinant Immunotoxin ◽  
Fda Approval

Abstract Moxetumomab pasudotox (MP) is an immunotoxin that recently received US Food and Drug Administration (FDA) approval for the treatment of hairy cell leukemia (HCL) that has failed at least 2 prior lines of therapy, including a purine analog. MP is a recombinant immunotoxin that consists of an anti-CD22 immunoglobulin variable domain genetically joined to Pseudomonas exotoxin (PE38). Unlike most antibody-drug conjugates, which use a chemical linker, recombinant DNA techniques are used to produce MP. MP and its predecessor, BL22, were initially developed to treat non-Hodgkin lymphoma, acute lymphoblastic leukemia, and HCL. However, MP was found to be particularly effective in HCL due to the high level of CD22 cell-surface expression. The recent pivotal phase 3 trial of MP in relapsed/refractory HCL demonstrated a durable complete remission rate of 30%, and 85% of complete responders achieved minimal residual disease negativity, which is associated with improved disease-free survival outcomes in HCL. In addition to an exceptional depth of response, MP appears to be less immunosuppressive than purine analogs. MP is generally well tolerated but has unique toxicities, including capillary leak syndrome and hemolytic uremic syndrome, which are poorly understood. This review will encompass the preclinical and clinical development of MP, with particular attention to its current indication in HCL.

Sign in / Sign up

Export Citation Format

Share Document